Compare Adaptive Biotechnologies Corp (ADPT) vs Honeywell International Inc (HON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Honeywell International Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while Honeywell International Inc trades at $222.15 (market cap $71.30B). The key difference: Honeywell International Inc is far larger — about 21.4× Adaptive Biotechnologies Corp's market cap, and Honeywell International Inc pays a 4.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HON | |
|---|---|---|
Market Cap | $3.33B | $71.30B |
Sector | Health | Industrials |
52-Week High | $22.37 | $248.04 |
52-Week Low | $10.24 | $188.14 |
Enterprise Value | $3.19B | $95.65B |
Dividend Yield | — | 4.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Honeywell Technologies (HON) trades at $225.05, down 2.09% today, following the completion of its aerospace spinoff on June 29, 2026. The stock shows strong fundamentals with a P/E of 18.46 and consistent earnings beats in recent quarters. Technical indicators suggest a bullish trend with support at $225 and resistance at $234. The company maintains solid profitability with 10.89% net margins and 26.41% ROE, though revenue declined slightly to $37.44B in 2025.
The outlook remains positive with 64% analyst buy ratings and a $402.40 consensus price target, representing 79% upside potential. Key risks include integration challenges from recent spinoffs and rising debt-to-asset ratio (46.65% in 2025). The company's focus on high-growth automation segments and ESG alignment provides long-term growth catalysts, though near-term volatility may persist during the post-spinoff transition period.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
